Joshua Gruber, MD, PhD
Joshua Gruber, M.D., Ph.D., is an Assistant Professor in the Department of Internal Medicine at UT Southwestern Medical Center. A breast cancer specialist, he has a secondary appointment in UTSW’s Cecil H. and Ida Green Center for Reproductive Biology Sciences.
Dr. Gruber earned his medical degree and doctoral degree in cancer biology and biochemistry at the University of Pennsylvania. He completed a residency in internal medicine at Stanford University, where he also received advanced training through a clinical fellowship in medical oncology and a research fellowship in systems biology of cancer epigenetics.
Certified by the American Board of Internal Medicine in medical oncology, he joined the UT Southwestern faculty in 2021.
Dr. Gruber is the author of numerous scholarly articles in journals such as Cell, Molecular Cell, and Cell Reports, and he serves as a peer reviewer for the Journal of Clinical Oncology Precision Oncology, Clinical Cancer Research, Nature Cancer and Nature Medicine.
His clinical focus is on treating patients with metastatic breast cancer and triple-negative breast cancer, as well as conducting early-stage clinical trials on new therapies for these diseases. His laboratory research interests include the molecular biology of breast cancer initiation, the intersection of tumor immunology with cancer growth pathways, and the development of molecular tools to interrogate neoplastic tissues.
He is also focused on gene regulation, specifically the intersection of cancer epigenetics with cellular metabolism. In particular, his work is directed at devising new methods for understanding how metabolic products affect chromatin landscapes as well as developing new chemical probes to interrogate this process.
Dr. Gruber is a member of the American Association for Cancer Research, the American Society of Clinical Oncology, and the Society for Immunotherapy of Cancer.
Financial relationships
-
Attribution:Spouse or PartnerType of financial relationship:EmploymentIneligible company:Guardant HealthTopic:ctDNADate added:09/07/2023Date updated:09/14/2024
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:Hummingbird BioscienceTopic:Cancer TherapeuticsDate added:09/07/2023Date updated:09/14/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:GuidepointTopic:OncologyDate added:09/07/2023Date updated:09/14/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Sharma TherapeuticsTopic:OncologyDate added:09/07/2023Date updated:09/14/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:HologicTopic:Diagnostics Breast CancerDate added:09/07/2023Date updated:09/14/2024Relationship end date:12/09/2022